Concepedia

Publication | Open Access

Sequential Cytarabine and α-Particle Immunotherapy with Bismuth-213–Lintuzumab (HuM195) for Acute Myeloid Leukemia

DOIFull Paper Access

260

Citations

35

References

2010

Year

Todd Rosenblat, Michael R. McDevitt, Deborah Mulford, Neeta Pandit‐Taskar, Chaitanya Divgi, Katherine S. Panageas, Mark Heaney, Suzanne Chanel, Alfred Morgenstern, George Sgouros,
Clinical Cancer Research

Abstract

Sequential administration of cytarabine and (213)Bi-lintuzumab is tolerable and can produce remissions in patients with AML.

References

YearCitations

Page 1